Report Library
All ReportsFollicular Lymphoma KOL Interview – Germany
September 30, 2022
This interview with a German KOL provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for follicular lymphoma. Future trends and unmet needs are also discussed. Key drug classes highlighted include anti-CD20 antibodies (Rituxan and Gazyva), immunomodulators (Revlimid), autologous CAR-T therapies (Yescarta and Kymriah), CD20 x CD3 bispecifics (Lunsumio), BTK inhibitors (Imbruvica and Brukinsa), EZH2 inhibitors (Tazverik), PI3 kinase inhibitors (Copiktra, Zydelig, Aliqopa, and zandelisib), and anti-CD19 antibodies (Monjuvi).
If you are a KOL Insight Subscriber, please access the interview from our KOL Insight portal (Subscribers only).
Biomedtracker will be offering KOL Reports and Physician Pulse Surveys for purchase a la carte, or access to all reports and surveys can be purchased as a subscription to KOL Insight. For more information on KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (858) 200-2357.
For our disclosures, please read the Biomedtracker Research Standards.
Indications Covered: | Follicular Lymphoma (FL) |
Additional Resources:
- Follicular Lymphoma KOL Interview – US (September 2022)
- Follicular Lymphoma KOL Interview – US (July 2021)
- Follicular Lymphoma KOL Interview – UK
- Datamonitor Healthcare Oncology Disease Analysis: NHL: Follicular Lymphoma
- 2022 Biomedtracker / Datamonitor Healthcare Post-ASCO Report
- 2021 Biomedtracker / Datamonitor Healthcare Post-ASH Report